Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
9
×
boston blog main
fda
9
×
life sciences
national blog main
san francisco blog main
9
×
biotech
boston top stories
clinical trials
national top stories
new york blog main
san francisco top stories
deals
investing
new york top stories
san diego blog main
roche
san diego top stories
akcea therapeutics
alnylam pharmaceuticals
boston university
drugs
eli lilly
eventide asset management
genentech
hereditary transthyretin amyloidosis
indiana blog main
inotersen
medical devices
patisiran
raleigh-durham blog main
rna interference
seattle blog main
tafamidis
venture capital
vyndaqel
akouos
aligos therapeutics
andrew fire
antibiotics
What
fda
drug
medicine
medicines
patients
alnylam
approved
biotechs
developing
device
ipo
ipos
medical
million
roche
startup
therapeutics
treat
way
acquire
affects
afternoon
ago
agreed
alnylam’s
americans
analytics
approval
approve
awaits
beta
big
billion
biofourmis
biological
bionics
blood
blueprint
broad
cancer
Language
unset
Current search:
boston
×
" san francisco blog main "
×
fda
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine